GHRP-2

What is GHRP-2?#

GHRP-2 (Growth Hormone Releasing Peptide-2), also known by its International Nonproprietary Name (INN) Pralmorelin and its developmental designation KP-102, is a synthetic hexapeptide growth hormone secretagogue (GHS) with the amino acid sequence D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2. It has a molecular weight of approximately 817.9 Da and the molecular formula C45H55N9O6. Its CAS registry number is 158861-67-7.

GHRP-2 belongs to the second generation of growth hormone releasing peptides, developed through systematic structure-activity optimization of the original GHS scaffold identified by Bowers and colleagues in the 1980s. The peptide incorporates three unnatural amino acids -- D-alanine, D-2-naphthylalanine, and D-phenylalanine -- that enhance receptor binding affinity, metabolic stability, and selectivity for the GHS-R1a receptor compared to earlier GHRPs.

Among the GHRP family, GHRP-2 is widely regarded as having the most favorable selectivity profile, producing robust GH release with comparatively less stimulation of cortisol, prolactin, and aldosterone than hexarelin or GHRP-6. This selectivity advantage, combined with its well-characterized pharmacology, has made GHRP-2 one of the most extensively studied GHS peptides in both preclinical and clinical settings.

Notably, GHRP-2 (as Pralmorelin) is approved in Japan as a diagnostic agent for evaluating growth hormone secretory capacity in patients with suspected GH deficiency, marketed under the trade name GHRP Kaken. This represents the only regulatory approval for a GHRP-class peptide in a major pharmaceutical market.

Mechanism of Action#

GHS-R1a Receptor Binding and Signal Transduction#

GHRP-2 stimulates GH release through activation of the GHS-R1a receptor (ghrelin receptor), a seven-transmembrane G protein-coupled receptor (GPCR) expressed on somatotroph cells of the anterior pituitary and on neurons in the hypothalamic arcuate nucleus. The GHS-R1a signals primarily through Gq/11-coupled phospholipase C (PLC) activation, generating inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from endoplasmic reticulum stores, while DAG activates protein kinase C (PKC). The resultant elevation of intracellular calcium concentration drives exocytosis of GH-containing secretory vesicles.

GHRP-2 binds to a site on the GHS-R1a that is distinct from the binding pocket engaged by the endogenous ligand ghrelin. Structural studies suggest that while both ligands activate the same receptor, they may stabilize partially different receptor conformations, potentially leading to subtle differences in downstream signaling bias. GHRP-2 does not require acylation for receptor binding, unlike ghrelin, which requires an octanoyl modification on its Ser3 residue for GHS-R1a activation.

Hypothalamic Modulation#

Beyond direct pituitary action, GHRP-2 modulates GH secretion at the hypothalamic level through two complementary mechanisms. First, it stimulates GHRH release from arcuate nucleus neurons, increasing the GHRH signal reaching the pituitary through the hypophyseal portal circulation. Second, it suppresses somatostatin (SRIF) release from the periventricular nucleus, reducing the tonic inhibitory tone that constrains GH secretion. This dual hypothalamic action, combined with direct pituitary stimulation, produces a more robust and physiologically patterned GH release than direct GHRH stimulation alone.

Synergistic Interaction with GHRH#

When GHRP-2 is co-administered with GHRH (or GHRH analogs), the resulting GH response is synergistic rather than merely additive. This synergy has been consistently demonstrated in clinical studies, with the combined GH response exceeding the sum of individual responses by a factor of two or more. The mechanistic basis for this synergy is the convergence of distinct intracellular signaling pathways: GHRH activates adenylyl cyclase through Gs-coupled signaling (cAMP/PKA pathway), while GHRP-2 activates PLC through Gq-coupled signaling. The concurrent activation of both cAMP and calcium/PKC pathways in somatotrophs produces a synergistic amplification of GH exocytosis.

This GHRH-GHRP synergy has been exploited clinically in Japan, where the combined GHRH plus GHRP-2 stimulation test is used to distinguish pituitary from hypothalamic causes of GH deficiency.

Appetite-Stimulating Effects#

As a GHS-R1a agonist, GHRP-2 mimics certain orexigenic effects of ghrelin. Activation of GHS-R1a in the arcuate nucleus stimulates neuropeptide Y (NPY) and agouti-related peptide (AgRP) expression while inhibiting proopiomelanocortin (POMC) neurons, shifting the hypothalamic energy balance toward increased appetite and food intake. In clinical studies, GHRP-2 has been shown to stimulate appetite and increase caloric intake, though these effects are less pronounced than those observed with GHRP-6 or native ghrelin.

Therapeutic Applications and Clinical Evidence#

Diagnostic Use in Japan (GHRP Kaken)#

The primary approved clinical application of GHRP-2 is as a diagnostic provocative test for growth hormone deficiency. In Japan, the GHRP-2 stimulation test (marketed as GHRP Kaken by Kaken Pharmaceutical) is used to assess the GH secretory capacity of the pituitary gland. The test involves intravenous administration of GHRP-2 at a dose of 100 micrograms, with serial blood sampling for GH measurement over the subsequent 60 to 120 minutes.

The diagnostic criteria define a peak GH response below a specified cutoff (typically 9 to 15 ng/mL depending on assay and clinical context) as suggestive of GH deficiency. The test demonstrates high sensitivity and specificity for severe GH deficiency and offers advantages over traditional provocative tests (insulin tolerance test, arginine stimulation) in terms of simplicity, reproducibility, and safety profile.

Validation studies in Japanese patient populations have demonstrated that the GHRP-2 test correlates well with the gold-standard insulin tolerance test while avoiding the risks of hypoglycemia. The combined GHRH plus GHRP-2 test further improves diagnostic accuracy and can help localize the defect to the hypothalamic or pituitary level.

Dose-Response Characterization#

Clinical pharmacology studies have established the dose-response relationship for GHRP-2-stimulated GH release in healthy adults. Intravenous doses ranging from 0.1 to 3.0 micrograms per kilogram produce dose-dependent increases in serum GH, with maximal responses typically observed at 1.0 to 2.0 micrograms per kilogram. Peak GH levels are achieved approximately 15 to 30 minutes after intravenous administration, with return to baseline within 2 to 3 hours.

Subcutaneous administration is also effective, producing a somewhat delayed and prolonged GH response with peak levels at 30 to 60 minutes. The subcutaneous route is preferred for repeated dosing in research protocols. Intranasal administration has been explored but shows variable bioavailability and less consistent GH responses.

Appetite and Cachexia Research#

The appetite-stimulating properties of GHRP-2 have generated interest in its potential application for conditions characterized by anorexia and cachexia, including cancer cachexia, chronic illness-related wasting, and anorexia nervosa. Clinical studies in patients with these conditions have demonstrated that GHRP-2 can increase caloric intake and improve nitrogen balance. However, these studies have generally been small and short-term, and definitive efficacy data from controlled trials are lacking.

In animal models of cachexia, GHRP-2 treatment has preserved lean body mass and improved survival, with effects attributed to both GH-mediated anabolism and direct ghrelin pathway activation of appetite circuits.

Comparison with Hexarelin and GHRP-6#

GHRP-2 occupies a middle ground in the GHRP family regarding potency and selectivity. Hexarelin generally produces higher peak GH levels but also stimulates more cortisol and prolactin release, and possesses unique CD36-mediated cardioprotective activity not shared by GHRP-2. GHRP-6 has stronger appetite-stimulating effects and was the first widely studied GHRP but shows less selectivity and potency than GHRP-2.

GHRP-2's relatively clean hormonal profile -- potent GH release with modest cortisol and prolactin elevation -- has made it a preferred research tool for studies focused specifically on the GH axis without the confounding variables introduced by more pronounced secondary hormonal effects.

Evidence Gaps and Limitations#

Limited Therapeutic Approvals#

Despite extensive characterization and its diagnostic approval in Japan, GHRP-2 has not been approved for therapeutic use in any jurisdiction. Its development as a therapeutic agent for GH deficiency or other indications has not progressed beyond Phase 2 studies. The availability of alternative GH-replacement strategies, including recombinant human GH and the GHRH analog tesamorelin, has reduced the commercial impetus for developing GHS-based therapeutics.

Desensitization with Chronic Use#

Like other GHS-R1a agonists, GHRP-2 is subject to tachyphylaxis with repeated administration. Studies of daily dosing show progressive attenuation of the GH response over one to four weeks, though the rate of desensitization appears somewhat slower for GHRP-2 compared to hexarelin. The mechanisms of desensitization include receptor internalization, upregulation of somatostatin tone, and possibly IGF-1-mediated negative feedback. Intermittent dosing protocols can partially mitigate this effect, but the optimal dosing strategy for sustained GH stimulation has not been established.

Incomplete Long-Term Safety Data#

The long-term safety profile of GHRP-2 in humans is poorly characterized. While short-term administration (days to weeks) in clinical studies has shown a generally favorable safety profile with transient facial flushing and mild injection-site reactions as the most common adverse effects, data on chronic exposure are lacking. Theoretical safety concerns include the effects of sustained ghrelin pathway activation on glucose metabolism (ghrelin opposes insulin action), body composition, and potential oncological implications of chronic GH/IGF-1 axis stimulation.

Limited Data Outside Japanese Populations#

The majority of clinical validation data for GHRP-2 as a diagnostic agent come from Japanese patient populations. The generalizability of the established diagnostic cutoff values and test performance characteristics to other ethnic and demographic groups has not been comprehensively evaluated. Population-specific differences in baseline GH secretion, body composition, and GHS-R1a expression could influence test interpretation.

Regulatory and Doping Considerations#

GHRP-2 is classified as a prohibited substance by the World Anti-Doping Agency (WADA) under the S2 category (peptide hormones, growth factors, related substances, and mimetics). It is detectable in urine by liquid chromatography-mass spectrometry (LC-MS/MS) methods, and anti-doping laboratories have developed validated assays for its detection. Outside of Japan's approved diagnostic use, GHRP-2 is available only as a research chemical and is not approved for human therapeutic use.

Key Research Findings#

Growth Hormone Releasing Peptide-2: A GH releasing signal integrated in the physiological regulatory cascade for GH secretion, published in Endocrine (Bowers CY et al., 1997):

Original characterization of GHRP-2 as a second-generation growth hormone releasing peptide with improved potency and selectivity compared to GHRP-6. Demonstrated dose-dependent GH release through GHS-R1a activation and characterized the synergistic interaction with GHRH.

• GHRP-2 produces dose-dependent GH release through a pathway distinct from GHRH
• Synergistic amplification of GH release when combined with GHRH exceeds the sum of individual responses
• GHRP-2 shows improved selectivity for GH release with reduced cortisol and prolactin effects compared to GHRP-6

Clinical evaluation of GHRP-2 (KP-102) as a GH secretion stimulation test in GH-deficient patients, published in Endocrine Journal (Doi M et al., 2004):

Key validation study for the Japanese diagnostic approval of GHRP-2 as a GH provocative test. Evaluated sensitivity and specificity of the GHRP-2 stimulation test compared to the insulin tolerance test in patients with suspected GH deficiency.

• GHRP-2 stimulation test showed high sensitivity and specificity for severe GH deficiency
• Diagnostic performance comparable to the insulin tolerance test with superior safety profile
• Peak GH cutoff values established for distinguishing GH-deficient from GH-sufficient patients

Evaluation of growth hormone secretion using the growth hormone-releasing peptide-2 test in healthy adults and patients with pituitary disease, published in Clinical Endocrinology (Korbonits M et al., 1999):

Characterized the GH secretory response to GHRP-2 in healthy adults and patients with various pituitary disorders. Established dose-response relationships and evaluated the test's utility for differentiating hypothalamic from pituitary causes of GH deficiency.

• Dose-dependent GH response with plateau at approximately 1-2 mcg/kg IV
• Patients with hypothalamic GH deficiency showed preserved responses while those with pituitary disease showed blunted responses
• Combined GHRH plus GHRP-2 testing improved diagnostic discrimination

Related Reading#

• GHRP-2 research studies and evidence
• GHRP-2 dosing protocols
• GHRP-2 side effects profile
• GHRP-6 research guide
• Sermorelin research guide